KYMRIAH DIN 02480514
Health Canada record
| Active ingredient(s) | TISAGENLECLEUCEL 600000000 CELLS |
|---|---|
| Dosage form | Suspension |
| Route | Intravenous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | L01XL04 TISAGENLECLEUCEL |
| Original market date | 24-May-2019 |
| Current status date | 24-May-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21274 | 2018-09-05 | New Drug Submission (NDS) | |
| 21273 | 2018-09-05 | New Drug Submission (NDS) |